Workforce and System Change to Treat Adolescent Opioid Use Disorder Within Integrated Pediatric Primary Care
Launched by INDIANA UNIVERSITY · Jun 25, 2024
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Adolescents are at increasing risk of overdose death. Since 2020, the overdose crisis has expanded most rapidly among younger populations, largely because of the recent reality that any illicit substance (e.g., counterfeit pharmaceuticals, methamphetamines) used by adolescents has the potential to contain lethal amounts of fentanyl. Preventing overdose deaths, therefore, necessitates identifying and treating youth - not only with opioid use disorder (OUD) - but any substance use disorder (SUD).
The investigators seek to ensure a robust workforce is available and equipped to deliver interve...
Gender
ALL
Eligibility criteria
- Inclusion Criteria for providers and staff recruited to complete surveys, focus groups, and/or interviews:
- • 1. member of participating pediatric primary care team
- • 2. at least 18 years old
- • 3. speaks and understanding English.
- Inclusion Criteria for administrative data:
- • 1. patient at one of the participating pediatric primary care team
- • 2. 12-18 years old
- Exclusion Criteria:
- • N/A
About Indiana University
Indiana University, a leading research institution, is committed to advancing healthcare through innovative clinical trials and rigorous scientific inquiry. With a focus on improving patient outcomes, the university conducts a wide range of studies across various medical disciplines, leveraging its extensive resources and collaborative networks. Indiana University's dedication to ethical research practices and community engagement ensures that its clinical trials not only contribute to scientific knowledge but also prioritize participant safety and well-being. Through its commitment to excellence, Indiana University plays a pivotal role in shaping the future of medicine and enhancing public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Indianapolis, Indiana, United States
Patients applied
Trial Officials
Leslie A Hulvershorn, MD
Principal Investigator
Indiana University/Indiana University Health
Zachary W Adams, PhD
Principal Investigator
Indiana University/Indiana University Health
Matthew C Aalsma, PhD
Principal Investigator
Indiana University/Indiana University Health
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported